Lipids and clotting factors during low dose transdermal estradiol/norethisterone use

Maturitas

Volumn 50, Issue 4, 2005, Pages 344-352

  Brynhildsen, Jan ^a   Hammar, Mats ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Coagulation; Continuous combined; Estradiol; Lipids; Low dose; Norethisterone acetate; Transdermal HRT

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; ESTRADIOL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; NORETHISTERONE ACETATE; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD CLOTTING; BREAST CARCINOMA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; FOLLOW UP; FRACTURE; HEART INFARCTION; HORMONE ACTION; HUMAN; LIPID ANALYSIS; LONG TERM CARE; MASTALGIA; MULTICENTER STUDY; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TRANSDERMAL PATCH;

EID: 14944347051     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.10.001     Document Type: Article

References (29)

1. E.R. Te Velde, and H.A. van Leusden Hormonal treatment for the climacteric: alleviation of symptoms and prevention of post-menopausal disease Lancet 343 1994 654 658
2. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer Lancet 350 1997 1047 1059
3. I. Persson, E. Weiderpass, L. Bergkvist, R. Bergstrom, and C. Schairer Risks of breast cancer and endometrial cancer after estrogen and estrogen-progestin replacement Cancer Causes Control 10 1999 253 260
4. T.L. Bush Extraskeletal effects of estrogen and the prevention of atherosclerosis Osteopor Int 2 1991 5 11
5. D. Grady, S.M. Rubin, and D.B. Petitti Hormone therapy to prevent disease and prolong life in postmenopausal women Ann Int Med 117 1992 1016 1037
6. E. Barrett-Connor The menopause, hormone replacement and cardiovascular disease: the epidemiologic evidence Maturitas 23 1996 227 234
7. E. Barrett-Connor, and T.L. Bush Estrogen and coronary heart disease in women JAMA 265 1991 1861 1867
8. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group JAMA 280 1998 605 613
9. D. Grady, D. Herrington, V. Bittner for the HERS Research Group Heart and estrogen/progestin replacement follow-up (HERS II). Part 1. Cardiovascular outcomes during 6.8 years of hormone therapy JAMA 288 2002 49 57
10. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized control trial JAMA 288 2002 321 333
11. S. Shapiro, J.P. Kelly, and L. Rosenberg Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens N Engl J Med 313 1985 969 972
12. W.H. Utian Transdermal estradiol overall safety profile Am J Obstet Gynecol 156 1987 1335 1338
13. S.A. Beresford, N.S. Weiss, L.F. Voight, and B. McKnight Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women Lancet 349 1997 458 461
14. E. Johannisson, C.F. Holinka, and S. Arrenbercht Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium Int J Fertil Womens Med 42 suppl 2 1997 388 398
15. S. Rozenberg, Ylirkorkala, and S. Arrenbrecht Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids Int J Fertil Womens Med 42 suppl 2 1997 376 387
16. R. Tepper, S. Goldberger, and I. Cohen Estrogen replacement in postmenopausal women: Are we currently overdosing our patients? Gynecol Obstet Invest 38 1994 113 116
17. J.A. Balfour, and R.C. Heel Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of menopausal complaints Drugs 40 1990 561 582
18. M.S. Powers, L. Schenkel, P.E. Darley, W.R. Good, J.C. Balestra, and V.A. Place Pharmacokinetics and pharmacodynamics of transdermal forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement Am J Obstet Gynecol 152 1985 1099 1106
19. S.C. Clarke, J. Kelleher, H. Lloyd-Jones, M. Slack, and P.M. Schofiel A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The PapworthHRT atherosclerosis study BJOG 109 2002 1056 1062
20. P.Y. Scarabin, E. Oger, G. Plu-Bureau Estrogen and Thromboembolism Risk Study Group Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428 432
21. A. Rubinacci, E. Peruzzi, A. Bacchi Modena, E. Zanardi, and B. Andrei Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone-loss in women Menopause 10 2003 241 249
22. J. Brynhildsen, and M. Hammar Low dose transdermal estradiol/ norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women Menopause 9 2002 137 144
23. L. Speroff, R.W. Whitcomb, and N.J. Kempfert Efficacy and local tolerance of a low dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms Obstet Gynecol 88 1996 587 592
24. E. Stadberg, L.A. Mattsson, and M. Uvebrant 17β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy Maturitas 23 1996 31 39
25. L.R. Weisman, and D. McTavish Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women Drugs Aging 4 1994 238 256
26. The writing group for the Estradiol Clotting Factors Study Effects on hemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year double-blind, placebo-controlled study Thromb Haemost 75 1996 476 480
27. C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 283 2000 485 491
28. Collaborative Group on Hormonal factors in breast cancer Breast cancer and hormonal contraceptives: further results Contraception 54 suppl 3 1996 lS 106S
29. H.A. Verheul, H.J. Coelingh-Bennink, P. Kenemans, and W.J. Atsma Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies Maturitas 36 2000 1 17